HILDEN, Germany and GERMANTOWN, Maryland, July 27, 2016 /PRNewswire/ --
PAXgene Blood ccfDNA enhances handling and workflow convenience for liquid biopsy applications in prenatal testing and cancer research
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the new PAXgene® Blood ccfDNA Tube* for venous whole blood collection and room temperature stabilization of in-vivo circulating cell-free DNA (ccfDNA) profiles.
Together with the QIAamp Circulating Nucleic Acid Kit - the gold standard in manual extraction of circulating cell-free DNA - and upcoming new automated ccfDNA isolation on the QIAsymphony, PAXgene Blood ccfDNA builds a fully integrated and complete standardized system covering all pre-analytical workflow steps from blood collection, stabilization, transport, storage and isolation of high quality ccfDNA.
The new system contains a unique non-crosslinking reagent in the collection tube that ensures DNA remains unmodified. It prevents post-collection release of genomic DNA from white blood cells - resulting in improved ccfDNA yield recovery with less background DNA. A minimized release of contents of ruptured red blood cells into blood plasma (hemolysis) enables a maximized plasma recovery, particularly critical in cancer research. Combined with the proven plastic BD Vacutainer® Tube technology, customers will benefit from consistent blood draws and no more glass tube breakage during the workflow.
Click here for full press release
Investor Relations: John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29-11711 Email: email@example.com ir.qiagen.com
SOURCE QIAGEN N.V.